BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Intarcia Therapeutics, Inc. Appoints Owen Hughes Chief Business Officer and Head of Corporate Development


2/5/2013 7:19:41 AM

HAYWARD, Calif., Feb. 5, 2013 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Owen Hughes, Jr., to the position of Chief Business Officer (CBO) and Head of Corporate Development. Mr. Hughes joins Intarcia from Brookside Capital, a multi-billion dollar hedge fund under the Bain Capital umbrella, where he served as a Director, co-managing all public and private healthcare investments. In his new position, Mr. Hughes will report directly to Intarcia Chairman, President and CEO Kurt Graves.

(Logo: http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

"I've known and respected Owen for many years for three key reasons. The first is his penetrating insights and tenacious 'in-it-to-win-it' spirit that will drive significant progress and results for our patients, our people, and our investors," said Mr. Graves. "The second quality is Owen's leadership, external focus and team-building demeanor that fits perfectly into our culture. Third, he is broadly plugged into where healthcare and technology is going and has built valuable relationships with many key players that will be important for our future success. We are thrilled to have him join our team!"

Mr. Hughes' leadership position is newly created at Intarcia and focuses on strategic planning, business operations, as well as oversight of all strategic transactions and business building collaborations. A primary objective will be to build an exciting pipeline with the Company's proprietary technology platforms. He will also work closely with the marketing team as Intarcia builds out new and forward-looking commercial models that fit the rapidly changing healthcare environment. Mr. Hughes' talents should prove very helpful to the Company during a time of intense strategic opportunity and growth.

Prior to working for Brookside Capital (Bain Capital), Mr. Hughes held steadily advancing positions at premier financial institutions, including Pyramis Global Advisors (a Fidelity Investment Company), Triathalon Fund Management LLC, Ziff Brothers Investments, Merrill Lynch / Morgan Stanley, and PaineWebber Incorporated. He graduated from Dartmouth College with a Bachelor of Arts in History. Mr. Hughes was an avid hockey player, having played varsity hockey at Dartmouth all four years, and received the Rookie of the Year Award in addition to subsequent honors in both sports and academics. He resides in the Boston area with his wife and family.

"It will be invigorating working with Owen, as he is very adept at making insightful choices and strategic investments based on his extraordinary sense of opportunities and where markets are going. But he also has amazing follow-up impact by knowing what has to get done tactically and how to be part of a high-performing team that executes to win," added Mr. Graves. "He's as fast-paced and exciting as the ice hockey he used to play. But he's also a good sportsman who never forgets team dynamics and what the real goal in healthcare is all about doing good for patients."

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.

SOURCE Intarcia Therapeutics, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES